Directly observed therapy to assess adherence in patient with apparent refractory hypertension. A case-report
https://doi.org/10.18705/2782-3806-2022-2-5-62-71
Abstract
Refractory arterial hypertension (RefHTN) is an extreme phenotype of resistant hypertension (RHTN), is associated with utmost poor clinical sequelae. True RHTN occurs in 10-15 % of treated patients. Up to half of them meet the definition of RefHTN, but another ~50 % are eventually diagnosed with ‘pseudo’-RHTN. Partial or complete non-adherence are among its the main causes. To date, there is no ‘gold’ standard to assess adherence. Directly observed therapy (DOT) is a promising non-invasive method to assess patient compliance. The wellknown abroad, DOT is not widely used in Russian clinical practice. In this short report we demonstrate a case of DOT in a patient with apparent RefHTN.
About the Authors
M. V. Ionov
Almazov National Medical Research Centre
Russian Federation
Russian Federation
MD, PhD, Researcher, Research Laboratory of Pathogenesis and Treatment of Hypertension, Department of Hypertension
I. V. Emelyanov
Almazov National Medical Research Centre
Russian Federation
Russian Federation
MD, PhD, Senior Researcher, Research Laboratory of Pathogenesis and Treatment of Hypertension, Department of Hypertension
A. O. Konradi
Almazov National Medical Research Centre
Russian Federation
Russian Federation
MD, PhD, DSc, Professor, Academic of RAS, Deputy General Director on Research, Head, Research Laboratory of Pathogenesis and Treatment of Hypertension, Research Department of Hypertension
References
1. Cheng S, Claggett B, Correia AW, et al. Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. Circulation 2014;130:820–8. https://doi.org/10.1161/CIRCULATIONAHA.113.008506.
2. Kario K, Nomura A, Harada N, et al. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB‐DH1 trial. J Clin Hypertens 2020;22:1713–22. https://doi.org/10.1111/jch.13993.
3. Egan BM, Kjeldsen SE, Grassi G, et al. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens 2019;37:1148–53. https://doi.org/10.1097/HJH.0000000000002021.
4. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertens Dallas Tex 1979 2018;72:e53–90. https://doi.org/10.1161/HYP.0000000000000084.
5. Bacan G, Ribeiro-Silva A, Oliveira VAS, Cardoso CRL, Salles GF. Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis. Curr Hypertens Rep 2022;24:95–106. https://doi.org/10.1007/s11906-022-01165-w.
6. Bhatt H, Siddiqui M, Judd E, et al. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens JASH 2016;10:493–9. https://doi.org/10.1016/j.jash.2016.03.186.
7. Burnier M, Vrijens B. Taxonomy of Medication Adherence: Recent Developments. In: Burnier M, editor. Drug Adherence Hypertens. Cardiovasc. Prot., Cham: Springer International Publishing; 2018, p. 1–8. https:// doi.org/10.1007/978-3-319-76593-8_1.
8. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021–104. https://doi.org/10.1093/eurheartj/ehy339.
9. Vrijens B, Antoniou S, Burnier M, et al. Current Situation of Medication Adherence in Hypertension. Front Pharmacol 2017;8. https://doi.org/10.3389/fphar.2017.00100.
10. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data metaanalysis. PLoS Med 2017;14:e1002389. https://doi.org/10.1371/journal.pmed.1002389.
11. Ionov MV, Zhukova OV, Yudina YS, et al. Valuebased approach to blood pressure telemonitoring and remote counseling in hypertensive patients. Blood Press 2021:20–30. https://doi.org/10.1080/08037051.2020.1813015.
12. Eskås PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press 2016;25:199–205. https://doi.org/10.3109/08037051.2015.1121706.
13. Out AA. Is the directly observed therapy short course (DOTS) an effective strategy for tuberculosis control in a developing country? Asian Pac J Trop Dis 2013;3:227–31. https://doi.org/10.1016/S2222-1808(13)60045-6.
14. Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet Lond Engl 2010;375:1814–29. https://doi.org/10.1016/S0140-6736(10)60483-7.
15. Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr 1999 2010;54:167–79. https://doi.org/10.1097/QAI.0b013e3181d9a330.
16. Beaney T, Schutte AE, Stergiou GS, et al. May Measurement Month 2019. Hypertension 2020;76:333–41. https://doi.org/10.1161/HYPERTENSIONAHA.120.14874.
17. Kobalava Z.D., Konradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. In Russian [Кобалава Ж.Д., Конради А.О., Недого- да С.В. и др. Артериальная гипертензия у взрос- лых. Клинические рекомендации 2020. // Россий- ский кардиологический журнал. 2020;25. https://doi.org/10.15829/1560-4071-2020-3-3786.]
18. Morisky DE, Green LW, Levine DM. Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence. Med Care 1986;24:67–74.
19. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021;39:1293–302. https://doi.org/10.1097/HJH.0000000000002843.
20. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertens Dallas Tex 1979 2017. https://doi.org/10.1161/HYP.0000000000000066.
21. Mariampillai JE, Eskås PA, Heimark S, et al. Apparent treatment-resistant hypertension - patientphysician relationship and ethical issues. Blood Press 2017;26:133–8. https://doi.org/10.1080/08037051.2016. 1277129.
22. Checchi KD, Huybrechts KF, Avorn J, et al. Electronic medication packaging devices and medication adherence: a systematic review. JAMA 2014;312:1237– 47. https://doi.org/10.1001/jama.2014.10059.
23. Stewart K, George J, Mc Namara KP, et al. A multifaceted pharmacist intervention to improve antihypertensive adherence: a cluster-randomized, controlled trial (HAPPy trial). J Clin Pharm Ther 2014;39:527–34. https://doi.org/10.1111/jcpt.12185.
24. Burnier M, Prejbisz A, Weber T, et al. Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Press 2021;30:282–90. https://doi.org/10.1080/08037051.2021.1963209.
25. Lukina YV, Martsevich SY, Kutishenko NP. The Moriscos-Green scale: the pros and cons of universal test, correction of mistakes. Ration Pharmacother Cardiol 2016;12:63–5.
26. Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs 2000;15:90–6.
27. Linicus Y, Kindermann I, Helfer AG, et al. Witnessed drug intake before planned denervation-- always harmless? Int J Cardiol 2015;179:125–6. https://doi.org/10.1016/j.ijcard.2014.10.162.
28. Feyz L, Bahmany S, Daemen J, et al. Therapeutic Drug Monitoring to Assess Drug Adherence in Assumed Resistant Hypertension: A Comparison With Directly Observed Therapy in 3 Nonadherent Patients. J Cardiovasc Pharmacol 2018;72:117–20. https://doi.org/10.1097/FJC.0000000000000602.
29. Pio-Abreu A, Trani-Ferreira F, Silva GV, et al. Directly observed therapy for resistant/refractory hypertension diagnosis and blood pressure control. Heart 2022. https://doi.org/10.1136/heartjnl-2022-320802.
30. Fadl Elmula FEM, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertens Dallas Tex 1979 2014;63:991–9. https://doi.org/10.1161/HYPERTENSIONAHA.114.03246.
31. Patel P, Gupta PKC, White CMJ, et al. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens 2016;30:368–73. https://doi.org/10.1038/jhh.2015.103.
32. Hameed MA, Tebbit L, Jacques N, et al. Nonadherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens 2016;30:83–9. https://doi.org/10.1038/jhh.2015.38.
Review
For citations:
Ionov M.V., Emelyanov I.V., Konradi A.O. Directly observed therapy to assess adherence in patient with apparent refractory hypertension. A case-report. Russian Journal for Personalized Medicine. 2022;2(5):62-71. (In Russ.) https://doi.org/10.18705/2782-3806-2022-2-5-62-71
Views:
272
Email this article 